ABL1 and glycogen storage disease VI: One finished study and two protocols investigate the potential use of imatinib, a BCR-ABL tyrosine kinase inhibitor, in patients with severe coronavirus disease 2019 (COVID-19) [47,48,50], as various authors reported findings that the use of imatinib may be beneficial in hospitalized patients with COVID-19 [120,121].